Online inquiry

IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8680MR)

This product GTTS-WQ8680MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets F3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001178096.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2152
UniProt ID P13726
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8680MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14846MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ13725MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ5902MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CIM 331
GTTS-WQ6252MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ11808MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ2212MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ4995MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ6184MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CP-870893
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW